Retinal Drugs Market, By Drug Class (Prostaglandins, Rho kinase inhibitor, Antihistamine, Anti-VEGF Agents, NSAIDs and Others), By Formulation, By Availability, By Indication, By Distribution Channel, By Country, and By Region Global Industry Analysis, Market Size, Market Share & Forecast from 2026-2033
|
Report ID
ANV5984
|
Published Date
September 2026
|
Pages
276
|
Industry
Healthcare
|
|
|
Base Year
2025
|
Historical Data
2019-2024
|
Delivery Timeline
24 Hour
|
REPORT HIGHLIGHT
Retinal Drugs market size was valued at US$ 24,201.3 Million in 2025, expanding at a CAGR of 8.1% from 2026 to 2033.
Retinal drugs can be defined as a set of medicinal agents that aid in treating different retinal diseases that involve the back portion of the eye that may include but not be limited to age-related macular degeneration (AMD), diabetic retinopathy (DR), and retinal vein occlusion (RVO) via regulation of angiogenesis, inflammation, and gene expression of the neural retina and choroid. Retinal drugs consist of a functional therapy agent (biologics for VEGF, suspensions of corticosteroids, or gene editing factors), an optimal delivery method (solutions, implants, microparticles, or cell delivery systems), and an intraocular administration technique (intravitreal injection) that makes use of the drug delivery kinetics and imaging guidance system. These therapies improve retinal disease management by enabling targeted treatment, sustained drug delivery, and better visual outcomes.
Retinal Drugs Market- Market Dynamics
Rising Prevalence of Retinal Disorders to Support Market Growth
The rising prevalence of retinal disorders is fuelling the Retinal Drugs market due to the increasing prevalence of conditions such as diabetic retinopathy and age-related macular degeneration, requiring effective treatments to avoid losing vision in the early stages of the development of the disease. For instance, in 2026, according to the European Commission’s CORDIS, as many as 420 million individuals were already suffering from one of the diseases of the retina by 2026, and this figure is expected to grow further in coming decades owing to an increased ratio of elderly individuals as well as those suffering from diabetes. According to the NeoVasculoStop project funded by the EU, the discovery and research into a class of active substances showed that some 25 compounds were found to have the potential to exert their action via a photo-induced interaction with the receptor, with the most potent substance being highly efficient even at extremely low doses in animals (rats and rabbits). These developments are speeding up the demand for new-edge solutions for the treatment of retinal disorders.
Retinal Drugs Market- Segmentation Analysis:
The Global Retinal Drugs market is segmented on the basis of Drug Class, Formulation, Availability, Indication, Distribution Channel, and Region.
By drug class, anti-VEGF agents hold a major share in the Retinal Drugs market because of the involvement of anti-VEGF medicines in the treatment of abnormal growth of blood vessels and their leakage in the treatment of age-related macular degeneration, diabetic macular oedema, and retinal vein occlusion. In April 2026, Regeneron obtained the FDA approval to extend the dosing interval of EYLEA HD® (aflibercept) 8 mg, an anti-VEGF medication, to every 20 weeks for patients with wet age-related macular degeneration and diabetic macular oedema. This development is anticipated to boost the usage of anti-VEGF medications through convenience.
Retinal Drugs Market- Geographical Insights
North America holds a prominent position in the global Retinal Drugs market because of the increase in cases of retinal diseases, improvement in drug development, and regulatory support. In May 2026, as reported by the U.S. Food and Drug Administration (Gov), the Center for Drug Evaluation and Research (CDER) has reviewed more than 500 drug applications that involve AI, indicating the application of AI in nonclinical, clinical, post-market, and manufacturing phases in the process of drug development in the US. Further, the US FDA had received more than 800 comments from the public on the discussion paper issued by the agency on the use of AI in drug development and also had set up the AI Council for managing such activities within the agency. Moreover, the US FDA and EMA have come up with 10 principles to encourage responsible use of AI in drug and biologics development. These advancements strengthen North America’s position through innovation, regulatory support, and AI-driven drug development.
Retinal Drugs Market- Competitive Landscape:
The Retinal Drugs market features a competitive landscape characterized by therapeutic innovation, a growing number of treatment alternatives, and increasing demand for effective retinal disease management. Key competitors are AbbVie Inc., Bayer AG, Alcon Inc., Alimera Sciences Inc., and Bausch Health Co. Inc. In January 2025, AbbVie and REGENXBIO will continue their cooperation concerning ABBV-RGX-314 for the treatment of retinal diseases and the development of the Phase 3 trial of this treatment in the case of diabetic retinopathy, as well as the continuation of pivotal trials in wet age-related macular degeneration in an attempt to make potential one-time therapies for retinal diseases available to patients. The companies have plans to conduct Phase 3 trials of this treatment in the case of diabetic retinopathy and continue pivotal trials in the case of wet age-related macular degeneration. These strategic advancements are expected to intensify competition and accelerate innovation in retinal disease treatments.
Recent Developments:
- In January 2026, Bayer was granted marketing authorization by the European Commission for Eylea 8 mg (aflibercept) in macular edema due to retinal vein occlusion, marking the third indication of the drug and allowing extended intervals between doses for patients.
- In September 2025, Alcon entered into an agreement to acquire LumiThera Inc., which has developed a light therapy, Valeda, for early and intermediate stages of dry age-related macular degeneration. This marked the expansion of the retinal health product line of Alcon into light therapies for dry AMD.
- In January 2025, Bausch + Lomb acquired Whitecap Biosciences with its pipeline of investigational agents for glaucoma and geographic atrophy, which is now its focus on retinal diseases related to vision impairment.
SCOPE OF THE REPORT
The scope of this report covers the market by its major segments, which include as follows:
GLOBAL RETINAL DRUGS MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS
- AbbVie Inc.
- Hoffmann-La Roche Ltd.
- Novartis AG
- Regeneron Pharmaceuticals Inc.
- Bayer AG
- Alcon Inc.
- Alimera Sciences Inc.
- Bausch + Lomb Corporation
- MeiraGTx Holdings plc
- Apellis Pharmaceuticals Inc.
- Amgen Inc.
- Santen Pharmaceutical Co. Ltd.
- EyePoint Pharmaceuticals Inc.
- Ocular Therapeutix Inc.
- Clearside Biomedical Inc.
- Adverum Biotechnologies Inc.
- Kodiak Sciences Inc.
- Astellas Pharma Inc.
- Others
GLOBAL RETINAL DRUGS MARKET, BY DRUG CLASS- MARKET ANALYSIS, 2020 - 2033
- Prostaglandins
- Rho kinase inhibitor
- Antihistamine
- Anti-VEGF Agents
- NSAIDs
- Others
GLOBAL RETINAL DRUGS MARKET, BY FORMULATION- MARKET ANALYSIS, 2020 - 2033
- Ointments
- Capsules & Tablets
- Eye Drops
- Gels
- Eye Solutions & Suspensions
GLOBAL RETINAL DRUGS MARKET, BY AVAILABILITY- MARKET ANALYSIS, 2020 - 2033
- Prescription Drugs
- OTC
GLOBAL RETINAL DRUGS MARKET, BY INDICATION- MARKET ANALYSIS, 2020 - 2033
- Infection
- Glaucoma
- Dry Eye
- Diabetic
- Retinopathy
- Allergies
- Others
GLOBAL RETINAL DRUGS MARKET, BY DISTRIBUTION CHANNEL- MARKET ANALYSIS, 2020 - 2033
- Online Pharmacies
- Hospital Pharmacies
- Retail Pharmacies
GLOBAL RETINAL DRUGS MARKET, BY REGION- MARKET ANALYSIS, 2020 - 2033
North America
- U.S.
- Canada
Europe
- Germany
- UK
- France
- Italy
- Spain
- The Netherlands
- Sweden
- Russia
- Poland
- Denmark
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Australia
- Indonesia
- Thailand
- Philippines
- Taiwan
- Vietnam
- Rest of APAC
Latin America
- Brazil
- Mexico
- Argentina
- Colombia
- Rest of LATAM
The Middle East and Africa
- Saudi Arabia
- UAE
- Israel
- Turkey
- Algeria
- Egypt
- Iran
- Qatar
- Rest of MEA
TABLE OF CONTENTS
1. Retinal Drugs Market Overview
1.1. Study Scope
1.2. Market Estimation Years
2. Executive Summary
2.1. Market Snippet
2.1.1. Retinal Drugs Market Snippet by Drug Class
2.1.2. Retinal Drugs Market Snippet by Formulation
2.1.3. Retinal Drugs Market Snippet by Availability
2.1.4. Retinal Drugs Market Snippet by Indication
2.1.5. Retinal Drugs Market Snippet by Distribution Channel
2.1.6. Retinal Drugs Market Snippet by Country
2.1.7. Retinal Drugs Market Snippet by Region
2.2. Competitive Insights
3. Retinal Drugs Key Market Trends
3.1. Retinal Drugs Market Drivers
3.1.1. Impact Analysis of Market Drivers
3.2. Retinal Drugs Market Restraints
3.2.1. Impact Analysis of Market Restraints
3.3. Retinal Drugs Market Opportunities
3.4. Retinal Drugs Market Future Trends
4. Retinal Drugs Industry Study
4.1. PEST Analysis
4.2. Porter’s Five Forces Analysis
4.3. Growth Prospect Mapping
4.4. Regulatory Framework Analysis
5. Retinal Drugs Market : Impact of Escalating Geopolitical Tensions
5.1. Impact of COVID-19 Pandemic
5.2. Impact of Russia-Ukraine War
5.3. Impact of Middle East Conflicts
6. Retinal Drugs Market Landscape
6.1. Retinal Drugs Market Share Analysis, 2025
6.2. Breakdown Data, by Key Manufacturer
6.2.1. Established Players’ Analysis
6.2.2. Emerging Players’ Analysis
7. Retinal Drugs Market – By Drug Class
7.1. Overview
7.1.1. Segment Share Analysis, By Drug Class, 2025 & 2033 (%)
7.1.2. Prostaglandins
7.1.3. Rho kinase inhibitor
7.1.4. Antihistamine
7.1.5. Anti-VEGF Agents
7.1.6. NSAIDs
7.1.7. Others
8. Retinal Drugs Market – By Formulation
8.1. Overview
8.1.1. Segment Share Analysis, By Formulation, 2025 & 2033 (%)
8.1.2. Ointments
8.1.3. Capsules & Tablets
8.1.4. Eye Drops
8.1.5. Gels
8.1.6. Eye Solutions & Suspensions
9. Retinal Drugs Market – By Availability
9.1. Overview
9.1.1. Segment Share Analysis, By Availability, 2025 & 2033 (%)
9.1.2. Prescription Drugs
9.1.3. OTC
10. Retinal Drugs Market – By Indication
10.1. Overview
10.1.1. Segment Share Analysis, By Indication, 2025 & 2033 (%)
10.1.2. Infection
10.1.3. Glaucoma
10.1.4. Dry Eye
10.1.5. Diabetic
10.1.6. Retinopathy
10.1.7. Allergies
10.1.8. Others
11. Retinal Drugs Market – By Distribution Channel
11.1. Overview
11.1.1. Segment Share Analysis, By Distribution Channel, 2025 & 2033 (%)
11.1.2. Online Pharmacies
11.1.3. Hospital Pharmacies
11.1.4. Retail Pharmacies
12. Retinal Drugs Market – By Geography
12.1. Introduction
12.1.1. Segment Share Analysis, By Geography, 2025 & 2033 (%)
12.2. North America
12.2.1. Overview
12.2.2. Retinal Drugs Key Manufacturers in North America
12.2.3. North America Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
12.2.4. North America Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
12.2.5. North America Market Size and Forecast, By Formulation, 2020 - 2033 (US$ Million)
12.2.6. North America Market Size and Forecast, By Availability, 2020 - 2033 (US$ Million)
12.2.7. North America Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
12.2.8. North America Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
12.2.9. U.S.
12.2.9.1. Overview
12.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
12.2.9.3. U.S. Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
12.2.9.4. U.S. Market Size and Forecast, By Formulation, 2020 - 2033 (US$ Million)
12.2.9.5. U.S. Market Size and Forecast, By Availability, 2020 - 2033 (US$ Million)
12.2.9.6. U.S. Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
12.2.9.7. U.S. Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
12.2.10. Canada
12.2.10.1. Overview
12.2.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
12.2.10.3. Canada Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
12.2.10.4. Canada Market Size and Forecast, By Formulation, 2020 - 2033 (US$ Million)
12.2.10.5. Canada Market Size and Forecast, By Availability, 2020 - 2033 (US$ Million)
12.2.10.6. Canada Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
12.2.10.7. Canada Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
12.3. Europe
12.3.1. Overview
12.3.2. Retinal Drugs Key Manufacturers in Europe
12.3.3. Europe Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
12.3.4. Europe Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
12.3.5. Europe Market Size and Forecast, By Formulation, 2020 - 2033 (US$ Million)
12.3.6. Europe Market Size and Forecast, By Availability, 2020 - 2033 (US$ Million)
12.3.7. Europe Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
12.3.8. Europe Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
12.3.9. Germany
12.3.9.1. Overview
12.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
12.3.9.3. Germany Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
12.3.9.4. Germany Market Size and Forecast, By Formulation, 2020 - 2033 (US$ Million)
12.3.9.5. Germany Market Size and Forecast, By Availability, 2020 - 2033 (US$ Million)
12.3.9.6. Germany Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
12.3.9.7. Germany Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
12.3.10. UK
12.3.10.1. Overview
12.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
12.3.10.3. UK Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
12.3.10.4. UK Market Size and Forecast, By Formulation, 2020 - 2033 (US$ Million)
12.3.10.5. UK Market Size and Forecast, By Availability, 2020 - 2033 (US$ Million)
12.3.10.6. UK Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
12.3.10.7. UK Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
12.3.11. France
12.3.11.1. Overview
12.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
12.3.11.3. France Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
12.3.11.4. France Market Size and Forecast, By Formulation, 2020 - 2033 (US$ Million)
12.3.11.5. France Market Size and Forecast, By Availability, 2020 - 2033 (US$ Million)
12.3.11.6. France Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
12.3.11.7. France Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
12.3.12. Italy
12.3.12.1. Overview
12.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
12.3.12.3. Italy Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
12.3.12.4. Italy Market Size and Forecast, By Formulation, 2020 - 2033 (US$ Million)
12.3.12.5. Italy Market Size and Forecast, By Availability, 2020 - 2033 (US$ Million)
12.3.12.6. Italy Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
12.3.12.7. Italy Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
12.3.13. Spain
12.3.13.1. Overview
12.3.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
12.3.13.3. Spain Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
12.3.13.4. Spain Market Size and Forecast, By Formulation, 2020 - 2033 (US$ Million)
12.3.13.5. Spain Market Size and Forecast, By Availability, 2020 - 2033 (US$ Million)
12.3.13.6. Spain Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
12.3.13.7. Spain Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
12.3.14. The Netherlands
12.3.14.1. Overview
12.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
12.3.14.3. The Netherlands Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
12.3.14.4. The Netherlands Market Size and Forecast, By Formulation, 2020 - 2033 (US$ Million)
12.3.14.5. The Netherlands Market Size and Forecast, By Availability, 2020 - 2033 (US$ Million)
12.3.14.6. The Netherlands Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
12.3.14.7. The Netherlands Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
12.3.15. Sweden
12.3.15.1. Overview
12.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
12.3.15.3. Sweden Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
12.3.15.4. Sweden Market Size and Forecast, By Formulation, 2020 - 2033 (US$ Million)
12.3.15.5. Sweden Market Size and Forecast, By Availability, 2020 - 2033 (US$ Million)
12.3.15.6. Sweden Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
12.3.15.7. Sweden Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
12.3.16. Russia
12.3.16.1. Overview
12.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
12.3.16.3. Russia Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
12.3.16.4. Russia Market Size and Forecast, By Formulation, 2020 - 2033 (US$ Million)
12.3.16.5. Russia Market Size and Forecast, By Availability, 2020 - 2033 (US$ Million)
12.3.16.6. Russia Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
12.3.16.7. Russia Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
12.3.17. Poland
12.3.17.1. Overview
12.3.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
12.3.17.3. Poland Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
12.3.17.4. Poland Market Size and Forecast, By Formulation, 2020 - 2033 (US$ Million)
12.3.17.5. Poland Market Size and Forecast, By Availability, 2020 - 2033 (US$ Million)
12.3.17.6. Poland Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
12.3.17.7. Poland Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
12.3.18. Denmark
12.3.18.1. Overview
12.3.18.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
12.3.18.3. Denmark Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
12.3.18.4. Denmark Market Size and Forecast, By Formulation, 2020 - 2033 (US$ Million)
12.3.18.5. Denmark Market Size and Forecast, By Availability, 2020 - 2033 (US$ Million)
12.3.18.6. Denmark Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
12.3.18.7. Denmark Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
12.3.19. Rest of Europe
12.3.19.1. Overview
12.3.19.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
12.3.19.3. Rest of the Europe Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
12.3.19.4. Rest of the Europe Market Size and Forecast, By Formulation, 2020 - 2033 (US$ Million)
12.3.19.5. Rest of the Europe Market Size and Forecast, By Availability, 2020 - 2033 (US$ Million)
12.3.19.6. Rest of the Europe Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
12.3.19.7. Rest of the Europe Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
12.4. Asia Pacific (APAC)
12.4.1. Overview
12.4.2. Retinal Drugs Key Manufacturers in Asia Pacific
12.4.3. APAC Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
12.4.4. APAC Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
12.4.5. APAC Market Size and Forecast, By Formulation, 2020 - 2033 (US$ Million)
12.4.6. APAC Market Size and Forecast, By Availability, 2020 - 2033 (US$ Million)
12.4.7. APAC Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
12.4.8. APAC Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
12.4.9. China
12.4.9.1. Overview
12.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
12.4.9.3. China Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
12.4.9.4. China Market Size and Forecast, By Formulation, 2020 - 2033 (US$ Million)
12.4.9.5. China Market Size and Forecast, By Availability, 2020 - 2033 (US$ Million)
12.4.9.6. China Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
12.4.9.7. China Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
12.4.10. India
12.4.10.1. Overview
12.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
12.4.10.3. India Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
12.4.10.4. India Market Size and Forecast, By Formulation, 2020 - 2033 (US$ Million)
12.4.10.5. India Market Size and Forecast, By Availability, 2020 - 2033 (US$ Million)
12.4.10.6. India Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
12.4.10.7. India Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
12.4.11. Japan
12.4.11.1. Overview
12.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
12.4.11.3. Japan Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
12.4.11.4. Japan Market Size and Forecast, By Formulation, 2020 - 2033 (US$ Million)
12.4.11.5. Japan Market Size and Forecast, By Availability, 2020 - 2033 (US$ Million)
12.4.11.6. Japan Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
12.4.11.7. Japan Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
12.4.12. South Korea
12.4.12.1. Overview
12.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
12.4.12.3. South Korea Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
12.4.12.4. South Korea Market Size and Forecast, By Formulation, 2020 - 2033 (US$ Million)
12.4.12.5. South Korea Market Size and Forecast, By Availability, 2020 - 2033 (US$ Million)
12.4.12.6. South Korea Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
12.4.12.7. South Korea Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
12.4.13. Australia
12.4.13.1. Overview
12.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
12.4.13.3. Australia Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
12.4.13.4. Australia Market Size and Forecast, By Formulation, 2020 - 2033 (US$ Million)
12.4.13.5. Australia Market Size and Forecast, By Availability, 2020 - 2033 (US$ Million)
12.4.13.6. Australia Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
12.4.13.7. Australia Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
12.4.14. Indonesia
12.4.14.1. Overview
12.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
12.4.14.3. Indonesia Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
12.4.14.4. Indonesia Market Size and Forecast, By Formulation, 2020 - 2033 (US$ Million)
12.4.14.5. Indonesia Market Size and Forecast, By Availability, 2020 - 2033 (US$ Million)
12.4.14.6. Indonesia Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
12.4.14.7. Indonesia Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
12.4.15. Thailand
12.4.15.1. Overview
12.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
12.4.15.3. Thailand Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
12.4.15.4. Thailand Market Size and Forecast, By Formulation, 2020 - 2033 (US$ Million)
12.4.15.5. Thailand Market Size and Forecast, By Availability, 2020 - 2033 (US$ Million)
12.4.15.6. Thailand Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
12.4.15.7. Thailand Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
12.4.16. Philippines
12.4.16.1. Overview
12.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
12.4.16.3. Philippines Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
12.4.16.4. Philippines Market Size and Forecast, By Formulation, 2020 - 2033 (US$ Million)
12.4.16.5. Philippines Market Size and Forecast, By Availability, 2020 - 2033 (US$ Million)
12.4.16.6. Philippines Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
12.4.16.7. Philippines Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
12.4.17. Taiwan
12.4.17.1. Overview
12.4.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
12.4.17.3. Taiwan Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
12.4.17.4. Taiwan Market Size and Forecast, By Formulation, 2020 - 2033 (US$ Million)
12.4.17.5. Taiwan Market Size and Forecast, By Availability, 2020 - 2033 (US$ Million)
12.4.17.6. Taiwan Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
12.4.17.7. Taiwan Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
12.4.18. Vietnam
12.4.18.1. Overview
12.4.18.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
12.4.18.3. Vietnam Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
12.4.18.4. Vietnam Market Size and Forecast, By Formulation, 2020 - 2033 (US$ Million)
12.4.18.5. Vietnam Market Size and Forecast, By Availability, 2020 - 2033 (US$ Million)
12.4.18.6. Vietnam Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
12.4.18.7. Vietnam Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
12.4.19. Rest of APAC
12.4.19.1. Overview
12.4.19.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
12.4.19.3. Rest of APAC Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
12.4.19.4. Rest of APAC Market Size and Forecast, By Formulation, 2020 - 2033 (US$ Million)
12.4.19.5. Rest of APAC Market Size and Forecast, By Availability, 2020 - 2033 (US$ Million)
12.4.19.6. Rest of APAC Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
12.4.19.7. Rest of APAC Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
12.5. Latin America (LATAM)
12.5.1. Overview
12.5.2. Retinal Drugs Key Manufacturers in Latin America
12.5.3. LATAM Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
12.5.4. LATAM Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
12.5.5. LATAM Market Size and Forecast, By Formulation, 2020 - 2033 (US$ Million)
12.5.6. LATAM Market Size and Forecast, By Availability, 2020 - 2033 (US$ Million)
12.5.7. LATAM Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
12.5.8. LATAM Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
12.5.9. Brazil
12.5.9.1. Overview
12.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
12.5.9.3. Brazil Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
12.5.9.4. Brazil Market Size and Forecast, By Formulation, 2020 - 2033 (US$ Million)
12.5.9.5. Brazil Market Size and Forecast, By Availability, 2020 - 2033 (US$ Million)
12.5.9.6. Brazil Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
12.5.9.7. Brazil Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
12.5.10. Mexico
12.5.10.1. Overview
12.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
12.5.10.3. Mexico Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
12.5.10.4. Mexico Market Size and Forecast, By Formulation, 2020 - 2033 (US$ Million)
12.5.10.5. Mexico Market Size and Forecast, By Availability, 2020 - 2033 (US$ Million)
12.5.10.6. Mexico Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
12.5.10.7. Mexico Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
12.5.11. Argentina
12.5.11.1. Overview
12.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
12.5.11.3. Argentina Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
12.5.11.4. Argentina Market Size and Forecast, By Formulation, 2020 - 2033 (US$ Million)
12.5.11.5. Argentina Market Size and Forecast, By Availability, 2020 - 2033 (US$ Million)
12.5.11.6. Argentina Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
12.5.11.7. Argentina Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
12.5.12. Colombia
12.5.12.1. Overview
12.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
12.5.12.3. Colombia Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
12.5.12.4. Colombia Market Size and Forecast, By Formulation, 2020 - 2033 (US$ Million)
12.5.12.5. Colombia Market Size and Forecast, By Availability, 2020 - 2033 (US$ Million)
12.5.12.6. Colombia Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
12.5.12.7. Colombia Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
12.5.13. Rest of LATAM
12.5.13.1. Overview
12.5.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
12.5.13.3. Rest of LATAM Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
12.5.13.4. Rest of LATAM Market Size and Forecast, By Formulation, 2020 - 2033 (US$ Million)
12.5.13.5. Rest of LATAM Market Size and Forecast, By Availability, 2020 - 2033 (US$ Million)
12.5.13.6. Rest of LATAM Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
12.5.13.7. Rest of LATAM Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
12.6. Middle East and Africa
12.6.1. Overview
12.6.2. Retinal Drugs Key Manufacturers in Middle East and Africa
12.6.3. Middle East and Africa Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
12.6.4. Middle East and Africa Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
12.6.5. Middle East and Africa Market Size and Forecast, By Formulation, 2020 - 2033 (US$ Million)
12.6.6. Middle East and Africa Market Size and Forecast, By Availability, 2020 - 2033 (US$ Million)
12.6.7. Middle East and Africa Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
12.6.8. Middle East and Africa Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
12.6.9. Saudi Arabia
12.6.9.1. Overview
12.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
12.6.9.3. Saudi Arabia Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
12.6.9.4. Saudi Arabia Market Size and Forecast, By Formulation, 2020 - 2033 (US$ Million)
12.6.9.5. Saudi Arabia Market Size and Forecast, By Availability, 2020 - 2033 (US$ Million)
12.6.9.6. Saudi Arabia Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
12.6.9.7. Saudi Arabia Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
12.6.10. United Arab Emirates
12.6.10.1. Overview
12.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
12.6.10.3. United Arab Emirates Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
12.6.10.4. United Arab Emirates Market Size and Forecast, By Formulation, 2020 - 2033 (US$ Million)
12.6.10.5. United Arab Emirates Market Size and Forecast, By Availability, 2020 - 2033 (US$ Million)
12.6.10.6. United Arab Emirates Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
12.6.10.7. United Arab Emirates Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
12.6.11. Israel
12.6.11.1. Overview
12.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
12.6.11.3. Israel Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
12.6.11.4. Israel Market Size and Forecast, By Formulation, 2020 - 2033 (US$ Million)
12.6.11.5. Israel Market Size and Forecast, By Availability, 2020 - 2033 (US$ Million)
12.6.11.6. Israel Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
12.6.11.7. Israel Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
12.6.12. Turkey
12.6.12.1. Overview
12.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
12.6.12.3. Turkey Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
12.6.12.4. Turkey Market Size and Forecast, By Formulation, 2020 - 2033 (US$ Million)
12.6.12.5. Turkey Market Size and Forecast, By Availability, 2020 - 2033 (US$ Million)
12.6.12.6. Turkey Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
12.6.12.7. Turkey Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
12.6.13. Algeria
12.6.13.1. Overview
12.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
12.6.13.3. Algeria Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
12.6.13.4. Algeria Market Size and Forecast, By Formulation, 2020 - 2033 (US$ Million)
12.6.13.5. Algeria Market Size and Forecast, By Availability, 2020 - 2033 (US$ Million)
12.6.13.6. Algeria Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
12.6.13.7. Algeria Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
12.6.14. Egypt
12.6.14.1. Overview
12.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
12.6.14.3. Egypt Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
12.6.14.4. Egypt Market Size and Forecast, By Formulation, 2020 - 2033 (US$ Million)
12.6.14.5. Egypt Market Size and Forecast, By Availability, 2020 - 2033 (US$ Million)
12.6.14.6. Egypt Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
12.6.14.7. Egypt Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
12.6.15. Iran
12.6.15.1. Overview
12.6.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
12.6.15.3. Iran Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
12.6.15.4. Iran Market Size and Forecast, By Formulation, 2020 - 2033 (US$ Million)
12.6.15.5. Iran Market Size and Forecast, By Availability, 2020 - 2033 (US$ Million)
12.6.15.6. Iran Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
12.6.15.7. Iran Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
12.6.16. Qatar
12.6.16.1. Overview
12.6.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
12.6.16.3. Qatar Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
12.6.16.4. Qatar Market Size and Forecast, By Formulation, 2020 - 2033 (US$ Million)
12.6.16.5. Qatar Market Size and Forecast, By Availability, 2020 - 2033 (US$ Million)
12.6.16.6. Qatar Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
12.6.16.7. Qatar Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
12.6.17. Rest of MEA
12.6.17.1. Overview
12.6.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
12.6.17.3. Rest of MEA Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
12.6.17.4. Rest of MEA Market Size and Forecast, By Formulation, 2020 - 2033 (US$ Million)
12.6.17.5. Rest of MEA Market Size and Forecast, By Availability, 2020 - 2033 (US$ Million)
12.6.17.6. Rest of MEA Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
12.6.17.7. Rest of MEA Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
13. Key Vendor Analysis- Retinal Drugs Industry
13.1. Competitive Benchmarking
13.1.1. Competitive Dashboard
13.1.2. Competitive Positioning
13.2. Company Profiles
13.2.1. AbbVie Inc.
13.2.2. F. Hoffmann-La Roche Ltd.
13.2.3. Novartis AG
13.2.4. Regeneron Pharmaceuticals Inc.
13.2.5. Bayer AG
13.2.6. Alcon Inc.
13.2.7. Alimera Sciences Inc.
13.2.8. Bausch + Lomb Corporation
13.2.9. MeiraGTx Holdings plc
13.2.10. Apellis Pharmaceuticals Inc.
13.2.11. Amgen Inc.
13.2.12. Santen Pharmaceutical Co. Ltd.
13.2.13. EyePoint Pharmaceuticals Inc.
13.2.14. Ocular Therapeutix Inc.
13.2.15. Clearside Biomedical Inc.
13.2.16. Adverum Biotechnologies Inc.
13.2.17. Kodiak Sciences Inc.
13.2.18. Astellas Pharma Inc.
13.2.19. Others
14. 360 Degree AnalystView
15. Appendix
15.1. Research Methodology
15.2. References
15.3. Abbreviations
15.4. Disclaimer
15.5. Contact Us
SCOPE OF THE REPORT
The scope of this report covers the market by its major segments, which include as follows:
GLOBAL RETINAL DRUGS MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS
- AbbVie Inc.
- Hoffmann-La Roche Ltd.
- Novartis AG
- Regeneron Pharmaceuticals Inc.
- Bayer AG
- Alcon Inc.
- Alimera Sciences Inc.
- Bausch + Lomb Corporation
- MeiraGTx Holdings plc
- Apellis Pharmaceuticals Inc.
- Amgen Inc.
- Santen Pharmaceutical Co. Ltd.
- EyePoint Pharmaceuticals Inc.
- Ocular Therapeutix Inc.
- Clearside Biomedical Inc.
- Adverum Biotechnologies Inc.
- Kodiak Sciences Inc.
- Astellas Pharma Inc.
- Others
GLOBAL RETINAL DRUGS MARKET, BY DRUG CLASS- MARKET ANALYSIS, 2020 - 2033
- Prostaglandins
- Rho kinase inhibitor
- Antihistamine
- Anti-VEGF Agents
- NSAIDs
- Others
GLOBAL RETINAL DRUGS MARKET, BY FORMULATION- MARKET ANALYSIS, 2020 - 2033
- Ointments
- Capsules & Tablets
- Eye Drops
- Gels
- Eye Solutions & Suspensions
GLOBAL RETINAL DRUGS MARKET, BY AVAILABILITY- MARKET ANALYSIS, 2020 - 2033
- Prescription Drugs
- OTC
GLOBAL RETINAL DRUGS MARKET, BY INDICATION- MARKET ANALYSIS, 2020 - 2033
- Infection
- Glaucoma
- Dry Eye
- Diabetic
- Retinopathy
- Allergies
- Others
GLOBAL RETINAL DRUGS MARKET, BY DISTRIBUTION CHANNEL- MARKET ANALYSIS, 2020 - 2033
- Online Pharmacies
- Hospital Pharmacies
- Retail Pharmacies
GLOBAL RETINAL DRUGS MARKET, BY REGION- MARKET ANALYSIS, 2020 - 2033
North America
- U.S.
- Canada
Europe
- Germany
- UK
- France
- Italy
- Spain
- The Netherlands
- Sweden
- Russia
- Poland
- Denmark
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Australia
- Indonesia
- Thailand
- Philippines
- Taiwan
- Vietnam
- Rest of APAC
Latin America
- Brazil
- Mexico
- Argentina
- Colombia
- Rest of LATAM
The Middle East and Africa
- Saudi Arabia
- UAE
- Israel
- Turkey
- Algeria
- Egypt
- Iran
- Qatar
- Rest of MEA
Related Reports
Credibility and Certifications
Trusted Insights, Certified Excellence! Coherent Market Insights is a certified data advisory and business consulting firm recognized by global institutes.
ISO 9001:2015
ESOMAR Corporate
GDPR Compliance
D-U-N-S Registered
BBB Accreditation
MRS
